Search database
Filter
31
Text search: Pfizer- BioNTech Comirnaty Vaccine
Featured
Language
Document type
Guidelines
14
Fact sheets
10
Online Courses
3
Manuals
2
Studies & Reports
2
Countries / Regions
Ukraine
4
Russia
4
China
3
Middle East and North Africa
3
Germany
2
Argentina
2
Brazil
2
Ecuador
2
South Africa
1
Paraguay
1
Kazakhstan
1
Belarus
1
Authors & Publishers
World Health Organization WHO
14
Open WHO
3
Ministerio de Salud Argentina
2
Ministerio de Salud Pública de Ecuador
2
Robert-Koch-Institut RKI, Deutsches Grünes Kreuz
2
Bracho C., Martinez C. et al.
1
Deutsches Grünes Kreuz e. V., Marburg, Robert Koch-Institut RKI
1
Dirección de Control de Enfermedades Inmunoprevenibles
1
Feraud, H.
1
Harding-Zentrum für Risikokompetenz
1
Health Cluster, WHO
1
Infection Prevention and Control UHL, WHO Headquarters
1
Mauder, S.
1
Ministerio da Saude, Brasilia
1
Organisation Mondiale de la Santé OMS
1
Organización Mundial de la Salud OMS
1
Robert-Koch-Instiut RKI
1
Sociedad Paraguaya de Pediatria
1
UNICEF
1
Wesern Cape Government, South Africa
1
World Health Organisation (WHO)
1
Publication Years
Category
Countries
14
Clinical Guidelines
1
Key Resources
1
Toolboxes
COVID-19
26
Refugee
2
Conflict
1
4 August 2021. Currently, Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) is the only COVID-19 ... more
Vaccinator's Manual. Pfizer-BioNTech Comirnaty Vaccine
Vaccine handling, storage and Transportation of Pfizer BioNTech COVID-19 COMIRNATY® (Tozinameran)
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab ... more
These WHO interim recommendations on the use of the PfizerBioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice iss ... more
Available in different languages
(Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та Spikevax® виробництва Moderna); Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019 ... more
– (Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та AUFKLÄRUNGSMERKBLATT Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und ... more
Health workers involved in deployment and implementation of COVID-19 vaccination require vaccine-specific knowledge to ensure safe and efficient vaccine delivery. This training provides key informat ... more
يحتاج العاملون الصحيون الذين يشاركون في نشر وتنفيذ التطعيم ضد كوفيد-19 إلى معرفة خاصة بكل لقاح لضمان تقديم اللقاحات بشكل آمن وفعال. يوفر هذا التدريب معلومات أساسية ح ... more
обновленная версия от 04/10/2021 Информация о введении вакцин
Временное руководство, Первый выпуск 8 января 2021 г., Обновлено 15 июня 2021 г., Обновлено 19 ноября 2021 г.
L’ensemble du personnel de santé qui participe au déploiement et à la mise en œuvre de la vaccination contre la COVID-19 doit avoir les connaissances et les compétences requises pour garantir une administration sûre et efficace du vaccin contre la COVID-19. Ce cours de formation fournit des ... more
orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna Stand 21. Dezember 2021
Overview 16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored ... more